BRT Apartments Corp. (MD) – Consensus Indicates Potential 24.4% Upside

DirectorsTalk Interviews

BRT Apartments Corp. (MD) found using ticker (BRT) have now 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 32 and 26 with the average target price sitting at 28.25. Given that the stocks previous close was at 22.71 this would indicate that there is a potential upside of 24.4%. The 50 day MA is 23.16 and the 200 day moving average is 22.21. The company has a market capitalisation of $437m. You can visit the company’s website by visiting: https://www.brtapartments.com

The potential market cap would be $544m based on the market concensus.

BRT is a real estate investment trust that owns, operates and develops multi-family properties.

Share on:

Latest Company News

India’s smart meter rollout is building a broader digital grid opportunity

India’s smart-meter rollout is developing into a wider digital-grid ecosystem spanning connected hardware, communications, utility software, cybersecurity and energy analytics.

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis.

GCP Infrastructure reports 8.0% portfolio yield and stronger balance sheet

GCP Infrastructure Investments has reported a 98.60 pence net asset value, portfolio valuation of £810.4 million and further debt and asset sale updates.

Plus500 expands US trading offering with new Single Stock Futures

Plus500 has launched Single Stock Futures in the US, broadening customer access to CME Group-listed contracts and leading US stocks.

Clarkson reports record first-half profit and raises interim dividend

Clarkson Plc reported record first-half profit, lifted interim dividend and said full-year performance is expected to be materially ahead of market expectations.

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

    Search